Litcius/Paper detail

Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic

Magali Chartier, Michael Desgagné, Marc Sousbie, Jérôme Côté, Jean‐Michel Longpré, Éric Marsault, Philippe Sarret

2021Journal of Medicinal Chemistry19 citationsDOIOpen Access PDF

Abstract

produces potent analgesia in three distinct rodent pain models, without causing the undesired effects associated with NTS1 activation. We further provide evidence of its non-opioid antinociceptive activity, therefore highlighting the strong therapeutic potential of NTS2-selective analogs for the management of acute and chronic pain.

Topics & Concepts

NeurotensinChemistryNeurotensin receptorIn vivoReceptorOpioidChemical synthesisStereochemistryPharmacologyCombinatorial chemistryIn vitroNeuropeptideBiochemistryMedicineBiologyBiotechnologyNeuropeptides and Animal PhysiologyReceptor Mechanisms and SignalingPain Mechanisms and Treatments
Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic | Litcius